Company Profile for Santarus, Inc.We are a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians. Our current efforts are primarily focused on the commercialization of ZEGERID[R] (omeprazole/sodium bicarbonate bicarbonate or hydrogen carbonate, chemical compound containing the bicarbonate radical, -HCO3. The most familiar of such compounds is sodium bicarbonate (baking soda). See carbonate. ) Capsules and Powder for Oral Suspension for the treatment of upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease gastroesophageal reflux disease (GERD) Disorder characterized by frequent passage of gastric contents from the stomach back into the esophagus. Symptoms of GERD may include heartburn, coughing, frequent clearing of the throat, and difficulty in swallowing. (GERD GERD gastroesophageal reflux disease. GERD abbr. gastroesophageal reflux disease GERD ). ZEGERID was developed by us based on our proprietary, immediate-release proton pump inhibitor proton pump inhibitor n. A class of drugs that inhibit gastric acid secretion by interfering with the movement of hydrogen ions across cell membranes and are used mainly to treat peptic ulcers, gastroesophageal reflux disease, and esophagitis. (PPI (1) (Pixels Per Inch) The measurement of the resolution of a monitor or scanner. For example, a monitor that is 16 inches wide and displays 1600 pixels across its width would have a resolution of 100 ppi (1600 divided by 16). ) technology. In the U.S. prescription market, our commercial organization promotes our ZEGERID products to a targeted group of gastroenterologists and primary care physicians who accounted for writing prescriptions for approximately one-third of the $14 billion market for PPIs in 2007. To further leverage our proprietary PPI technology and diversify our sources of revenue, we have entered into strategic alliances with two global pharmaceutical companies. Our goal is to become a leading specialty pharmaceutical company. We plan to continue to seek to maximize the value of our PPI technology, as well as expand our product portfolio through co-promotion, licensing or acquisition of marketed or late stage proprietary products. [TABLE OMITTED] |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion